Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.
ALTERITY THERAPEUTICS LTD (ATHE) entered into an Underwriting Agreement with MST Financial Services Pty Ltd, which has agreed to underwrite the exercise of up to 8,400,000 unexercised ATHO listed options ahead of their expiry. These Underwritten Options are expected to raise approximately A$4.2 million before costs.
There are currently 15,918,235 ATHO options on issue, exercisable at A$0.50 and expiring at 5:00pm (AEST) on 31 August 2026. Subject to completion of the underwriting and depending on how many options are exercised by holders, Alterity will issue between 8,400,000 and 15,918,235 new shares and raise approximately A$4.2–7.96 million before costs.
The underwriter will receive a 7% fee on gross proceeds from underwritten option exercises and may allocate Underwritten Shares to sub-underwriters that are sophisticated and professional investors. Proceeds are expected to support late-stage clinical development of ATH434 in Multiple System Atrophy and general working capital. The agreement includes customary conditions and termination events and may be terminated by either party in specified circumstances.
ALTERITY THERAPEUTICS LIMITED (ATHE) filed an annual report describing its development-stage neurology business focused on ATH434 for multiple system atrophy (MSA) and other Parkinsonian disorders. ATH434 is the lead and highly concentrated asset; Alterity reported positive FDA feedback and End‑of‑Phase 2 alignment on key elements of a registrational Phase 3 program.
The company’s ordinary shares trade primarily on the ASX and its American Depositary Shares, each representing 12 ordinary shares, trade on the Nasdaq Capital Market under “ATHE.” Ordinary shares outstanding were 217,508,862 as of June 30, 2026. Financial statements are prepared in Australian dollars under IFRS.
Alterity reported operating losses of A$23.4 million in fiscal 2026 and A$12.1 million in 2025, with operating cash outflows of A$22.5 million and A$11.5 million, and expects continued losses and substantial additional capital needs. The report highlights extensive clinical, regulatory, manufacturing, data‑privacy, intellectual property, healthcare policy, currency, listing‑compliance, geopolitical and Australian‑jurisdiction risks, including PFIC tax risk for certain U.S. holders and potential dilution from future financings.
Alterity Therapeutics Limited reports that the U.S. Patent and Trademark Office has granted a new composition of matter patent for ATH434, its lead clinical asset for Multiple System Atrophy (MSA), Parkinson’s disease and related disorders. The patent covers a crystalline form of ATH434 mesylate and associated treatment methods and extends protection to at least 2045, adding a key layer of intellectual property as ATH434 moves toward planned Phase 3 development in MSA by year-end 2026. The company notes that this protection supports potential commercial value, partnership opportunities and expansion of ATH434 into Parkinson’s disease and other neurodegenerative indications, alongside existing Fast Track and Orphan Drug Designations for MSA.
Alterity Therapeutics Limited reports that Chief Executive Officer David Stamler, M.D., will present at the 46th Annual Canaccord Genuity Growth Conference on August 11, 2026 at 1:30 p.m. ET, with a live and archived webcast available through the company’s investor website.
The biotechnology company focuses on disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders and is preparing to initiate a Phase 3 pivotal trial in MSA. Lead asset ATH434 has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and has also generated positive data in an open-label Phase 2 trial in participants with advanced MSA.
Alterity Therapeutics Limited reported a pivotal quarter, securing FDA alignment at an End-of-Phase 2 meeting on the registrational pathway for ATH434 in Multiple System Atrophy. The agency indicated that a single pivotal Phase 3 trial plus confirmatory evidence, anticipated from the ATH434-201 Phase 2 study, could support a New Drug Application.
The planned Phase 3 trial will enroll about 200 patients, randomized 1:1 to ATH434 50 mg or placebo twice daily for 12 months, using the 11-item UMSARS Part I scale as the primary endpoint and offering an open-label extension. Alterity has also manufactured the first registration batch of ATH434 and received positive FDA Type C feedback on chemistry, manufacturing and control elements.
Strategic partnering and funding discussions with pharmaceutical companies continue alongside other financing options. As of 30 June 2026, cash and cash equivalents were A$37.3 million, with quarterly operating cash outflows of A$7.72 million and an estimated 5.2 quarters of funding available. A 1-for-50 share consolidation was completed following shareholder approval.